Navigating 5 Analyst Ratings For Prothena Corp
Portfolio Pulse from Benzinga Insights
Prothena Corp (NASDAQ:PRTA) has received mixed analyst ratings over the past three months, with 1 bullish, 3 somewhat bullish, and 1 indifferent. The average 12-month price target is $79.0, down from $85.00, with a high of $129.00 and a low of $36.00. Analysts from RBC Capital, Cantor Fitzgerald, Deutsche Bank, and JMP Securities have adjusted their ratings and price targets. Prothena's financial performance shows a revenue growth of 5494.33%, a net margin of 25.81%, an ROE of 3.65%, an ROA of 2.99%, and a low debt-to-equity ratio of 0.02.

January 25, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Prothena Corp has a diverse range of analyst ratings and a downward revision in the average price target. The company's strong financial performance is highlighted by significant revenue growth and profitability metrics.
The mixed analyst ratings and the decrease in the average price target suggest uncertainty, which could lead to a neutral short-term impact on PRTA's stock price. However, the company's strong financial performance, particularly in revenue growth and profitability, could counterbalance the negative sentiment from the lowered price targets. The high relevance is due to the direct mention of PRTA and the detailed analysis of its financials and analyst ratings. The importance is high as analyst ratings are a significant factor for investors, but not at the maximum because other market factors also play a role. The confidence level is set at 80, reflecting the clear data provided but acknowledging the unpredictable nature of market reactions.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100